3182. Tominersen in Adults with Manifest Huntington's Disease.
作者: Peter McColgan.;Alpa Thobhani.;Lauren Boak.;Scott A Schobel.;Alessia Nicotra.;Giuseppe Palermo.;Dylan Trundell.;Julian Zhou.;Valerie Schlegel.;Patricia Sanwald Ducray.;David J Hawellek.;Jonas Dorn.;Cedric Simillion.;Michael Lindemann.;Vicki Wheelock.;Alexandra Durr.;Karen E Anderson.;Jeffrey D Long.;Edward J Wild.;G Bernhard Landwehrmeyer.;Blair R Leavitt.;Sarah J Tabrizi.;Rachelle Doody.; .
来源: N Engl J Med. 2023年389卷23期2203-2205页 3189. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
作者: Kathleen N Moore.;Antoine Angelergues.;Gottfried E Konecny.;Yolanda García.;Susana Banerjee.;Domenica Lorusso.;Jung-Yun Lee.;John W Moroney.;Nicoletta Colombo.;Andrzej Roszak.;Jacqueline Tromp.;Tashanna Myers.;Jeong-Won Lee.;Mario Beiner.;Casey M Cosgrove.;David Cibula.;Lainie P Martin.;Renaud Sabatier.;Joseph Buscema.;Purificación Estévez-García.;Lan Coffman.;Shibani Nicum.;Linda R Duska.;Sandro Pignata.;Fernando Gálvez.;Yuemei Wang.;Michael Method.;Anna Berkenblit.;Diana Bello Roufai.;Toon Van Gorp.; .
来源: N Engl J Med. 2023年389卷23期2162-2174页
Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United States.
3190. Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.
作者: Michaela Waibel.;John M Wentworth.;Michelle So.;Jennifer J Couper.;Fergus J Cameron.;Richard J MacIsaac.;Gabby Atlas.;Alexandra Gorelik.;Sara Litwak.;Laura Sanz-Villanueva.;Prerak Trivedi.;Simi Ahmed.;Francis J Martin.;Madeleine E Doyle.;Jessica E Harbison.;Candice Hall.;Balasubramanian Krishnamurthy.;Peter G Colman.;Leonard C Harrison.;Helen E Thomas.;Thomas W H Kay.; .
来源: N Engl J Med. 2023年389卷23期2140-2150页
Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell function in type 1 diabetes is unclear.
|